Pancreatic Cancer in 2025: Nearing an Inflection Point

Udhayvir Singh Grewal, MD Winship Cancer Institute of Emory University

The past year in pancreatic ductal adenocarcinoma (PDAC) research reflects a field at an inflection point. While conventional cytotoxic intensification continues to deliver modest gains, emerging data increasingly emphasize biological selection, novel therapeutic modalities, and molecularly guided strategies as the most promising paths forward. Recent clinical trials, translational studies, and early-phase evaluations of novel therapies collectively underscore both the limits of chemotherapy escalation and the growing momentum toward a precision oncology-driven era in PDAC care.

Perioperative Lessons in PDAC

In resectable and borderline resectable PDAC, the PREOPANC-2 trial provided a sobering but clarifying result. This large, investigator-initiated phase 3 study demonstrated no overall survival (OS) difference between neoadjuvant FOLFIRINOX and neoadjuvant gemcitabine-based chemoradiotherapy followed by adjuvant gemcitabine, with a median OS of approximately 22 months in both arms. Although toxicity profiles differed, most notably higher gastrointestinal toxicity with FOLFIRINOX, the overall burden of grade 3 or higher adverse events (AEs) was comparable. These data reinforce that multiple neoadjuvant strategies remain valid and that intensified systemic therapy does not uniformly translate into improved survival in unselected patients.

In contrast, the PACT-21 CASSANDRA trial introduced a potentially practice-shifting signal. In this randomized phase 3 study, perioperative PAXG (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) significantly improved event-free survival (EFS) compared with modified FOLFIRINOX (16 vs 10.2 months; HR, 0.63). While OSdata are still immature, the magnitude of EFS benefit suggests that alternative multi-agent backbones, particularly those incorporating platinum agents, may outperform FOLFIRINOX in selected perioperative settings and could be considered as comparators in future trials.

PRODIGE 29 Data Shows PFS Gains

For locally advanced pancreatic cancer, PRODIGE 29 (NEOPAN) demonstrated the complexity of translating disease control into survival benefit. FOLFIRINOX improved progression-free survival (PFS) compared with gemcitabine, yet OS remained nearly identical between arms. This recurring pattern highlights the need for improved consolidation strategies, better local control, or biologically targeted approaches to convert early gains into durable benefit. Real progress in PDAC in the future will be built upon targeted/personalized therapeutic approaches instead of chemotherapy alone. 

PANOVA-3: Tumor Treating Fields Deliver an OS Benefit

One of the more notable advances of the year came from PANOVA-3, a pivotal phase 3 trial evaluating tumor treating fields (TTFields) combined with gemcitabine and nab-paclitaxel in unresectable locally advanced PDAC. The addition of TTFields resulted in a statistically significant improvement in OS (16.2 vs 14.2 months; HR, 0.82), along with prolonged pain-free survival and distant PFS, without increasing systemic toxicity. Although device-related dermatologic AEs were common, they were largely manageable. PANOVA-3 represents a rare example of a non-pharmacologic modality achieving an OS benefit in PDAC and broadens the therapeutic toolkit beyond chemotherapy alone. However, concerns over cost, magnitude of benefit in the real-world setting, and patient adherence among other barriers may limit adoption in clinical practice. 

Precision Oncology Comes Into Focus

Targeted and biologically driven approaches continue to gain momentum in PDAC. At the 2025 ASCO Gastrointestinal Cancers Symposium, daraxonrasib (RMC-6236), a first-in-class RAS(ON) multi-selective inhibitor, demonstrated encouraging activity in previously treated RAS-mutant PDAC, with manageable toxicity and early, deep reductions in RAS-mutant circulating tumor DNA. These molecular responses provide proof-of-concept that directly targeting active RAS signaling—long considered intractable—may be feasible. The ongoing phase 3 RASolute 302 trial will be critical in determining whether these early signals translate into meaningful survival benefit.

It is also encouraging to see progress beyond more traditional targeted approaches as the first-in-human phase 1 study of NW-301V, an autologous T-cell receptor–engineered T-cell (TCR-T) therapy targeting KRAS G12V in HLA-A*11:01–positive solid tumors was presented at the 2025 ESMO Annual Congress. This study evaluated three dose levels in 14 patients with advanced pancreatic or colorectal cancer who lacked alternative treatment options. Importantly, NW-301V demonstrated a favorable safety profile, with no severe treatment-related toxicities beyond expected lymphodepletion effects, no immune effector cell-associated neurotoxicity syndrome, and only grade 1–2 cytokine release syndrome in fewer than half of patients. Preliminary efficacy was notable for a heavily pretreated population: the overall objective response rate was 42.9%, and among patients treated at higher dose levels, half achieved partial responses while the remainder had stable disease, with a median PFS of 5.8 months. While early and limited by small numbers, these results represent a compelling proof-of-principle for mutation-specific cellular therapy in PDAC.

The Road Ahead in PDAC

Taken together, the past year underscores a central theme in PDAC research: chemotherapy intensification alone has reached diminishing returns, while meaningful progress is increasingly tied to biological insight and therapeutic innovation. The growing body of evidence demonstrating promise of personalized therapies points toward a future in which treatment selection is more precise and biology-driven. This is encouraging news for patients and families who are affected by this deadly disease each year, as well as for those who continue to work to improve outcomes and quality of life.